We are joining forces with Canaccord Genuity
We are very excited to share that we have agreed to join forces with Canaccord Genuity – a leading full-service investment bank serving growth companies in the middle market. This is an important milestone in our journey and we wanted to update you on why we’ve taken this decision and what it means for you.
Since it was founded in 1988, Results has grown into a leading independent sector-focussed advisory firm, advising corporate, founder-owned and private equity clients on transactions in the healthcare and technology sectors. We’ve advised on over 60 transactions in our focus sectors in the last three years alone. The combination with Canaccord Genuity will enable us to enhance our global reach, expand our advisory capability and continue to deliver outstanding outcomes for our clients.
What We Do
We’ve been providing independent M&A and corporate finance advice and execution services to entrepreneurs, corporates and investors in the technology and healthcare sectors for over 30 years. Whether your aim is to realise value or to find a partner for future growth, we will be your partner
When the time comes, we’re by your side every step of the way. We help you evaluate your market, find the right buyer, and deliver the true value of your business
With a strong track record in company carve-outs, we can help you realign your portfolio and redeploy capital to the growth of your core business
We support clients with in-licensing and out-licensing of drugs, technologies and facilities. We understand the complexities that are unique to licensing deals
We understand that optimising terms is critical, but so is finding the right partner for growth. We help articulate your equity story, target the best investors and negotiate the right deal
Having completed over 300 transactions, we bring the breadth of perspectives and depth of business experience to provide advice on strategic options for businesses
The Global Technology Market Review – Q2 2022
Private deal activity and valuations within the global technology market remain high in spite of macroeconomic uncertainty. M&A continues to be driven by further adoption of cloud and next-gen technologies, increased focus on strategic tuck-ins, and launching in new markets. As geopolitical uncertainty continues to impact public markets, the outlook for the second half of […]
CRO Sector – M&A drivers and market trends – Q1 2022
Whilst the pandemic has caused unprecedented disruption on research and clinical trials, it has also launched the clinical trial landscape into a new area, one with the enhanced utilisation of decentralised trials and the long-awaited embracement of digital technologies to deliver improved patient care, reduced clinical trial costs and speedier outcomes. We have also seen […]